Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Nonrelated Party	Related Party	Preferred stock	Preferred stock Nonrelated Party	Common stock	Common stock Nonrelated Party	Common stock Related Party	Additional paid-in Capital	Additional paid-in Capital Nonrelated Party	Additional paid-in Capital Related Party	Accumulated other comprehensive income (loss)	Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2021				1,969,797
Beginning balance (in shares) at Dec. 31, 2021						17,103,395
Beginning balance at Dec. 31, 2021	$ 196,107			$ 0		$ 2			$ 863,495			$ (80)	$ (667,310)
Increase (Decrease) in Stockholders' Equity
Issuance of common and preferred shares in equity offerings, excluding to related parties, net of transaction costs (in shares)					400,000		783,344
Issuance of common shares in equity offerings, excluding to related parties, net of transaction costs		$ 255,382								$ 255,382
Sale of warrants and common shares to related parties and exercise of common stock options, net of transaction costs (in shares)								215,784
Sale of warrants and common shares to related parties and exercise of common stock options, net of transaction costs			$ 8,955								$ 8,955
Stock-based compensation expense related to equity-classified awards	31,625								31,625
Unrealized gain on marketable securities	48											48
Hercules warrant	622								622
Net Loss	(295,350)												(295,350)
Ending balance (in shares) at Dec. 31, 2022				2,369,797
Ending balance at Dec. 31, 2022	197,389			$ 0		$ 2			1,160,079			(32)	(962,660)
Ending balance (in shares) at Dec. 31, 2022						18,102,523
Increase (Decrease) in Stockholders' Equity
Issuance of common and preferred shares in equity offerings, excluding to related parties, net of transaction costs (in shares)							1,346,199
Issuance of common shares in equity offerings, excluding to related parties, net of transaction costs		260,187								260,187
Sale of warrants and common shares to related parties and exercise of common stock options, net of transaction costs (in shares)								426,705
Sale of warrants and common shares to related parties and exercise of common stock options, net of transaction costs			270,292								270,292
Stock-based compensation expense related to equity-classified awards	49,735								49,735
Unrealized gain on marketable securities	500											500
Hercules warrant	860								860
Net Loss	$ (373,630)												(373,630)
Ending balance (in shares) at Dec. 31, 2023	2,369,797			2,369,797
Ending balance at Dec. 31, 2023	$ 405,333			$ 0		$ 2			1,741,153			468	(1,336,290)
Ending balance (in shares) at Dec. 31, 2023	19,875,427					19,875,427
Increase (Decrease) in Stockholders' Equity
Issuance of common and preferred shares in equity offerings, excluding to related parties, net of transaction costs (in shares)							1,096,153
Issuance of common shares in equity offerings, excluding to related parties, net of transaction costs		$ 397,487								$ 397,487
Sale of warrants and common shares to related parties and exercise of common stock options, net of transaction costs (in shares)	928,800							1,033,099
Sale of warrants and common shares to related parties and exercise of common stock options, net of transaction costs			$ 337,575								$ 337,575
Compensation expense related to stock options for services (in shares)						0
Stock-based compensation expense related to equity-classified awards	$ 79,880								79,880
Unrealized gain on marketable securities	0
Net Loss	$ (465,892)												(465,892)
Ending balance (in shares) at Dec. 31, 2024	2,369,797			2,369,797
Ending balance at Dec. 31, 2024	$ 754,383			$ 0		$ 2			$ 2,556,095			$ 468	$ (1,802,182)
Ending balance (in shares) at Dec. 31, 2024	22,004,679					22,004,679